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Delayed puberty secondary to hypogonadism is commonly seen in sickle cell disease (SCD), affecting
normal growth and development. The condition is rarely treated in SCD for fear of inducing priapism
episodes. We present a case report of an Afro-Jamaican adolescent male at 16 years of age who presented
with symptoms of delayed puberty as well as frequent stuttering priapism episodes. Endocrinological
assessment revealed low serum total testosterone levels. Treatment was commenced monthly with
testosterone enanthate which resulted in improved symptoms of delayed puberty, improvement in
anthropometric parameters while apparently ameliorating priapism episodes.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Delayed puberty in boys is deﬁned as the absence of testicular
development at an age 2e2.5 SD later than the population mean,
which is traditionally 14 years.1 It may be classiﬁed as hypo-
gonadotropic hypogonadism, hypergonadotropic hypogonadism or
constitutional delay in puberty. Delayed puberty results in a delay
in the attainment of secondary sexual characteristics, pubertal
growth spurt and skeletal maturation. It may negatively affect the
psychosocial development of the affected boy.
Delayed puberty has been previously described in males with
sickle cell disease (SCD). In several cases of delayed puberty,
treatment with androgensmay be initiated to improve psychosocial
effects. However this is not commonly practiced in SCD, as it is
thought that androgen administration is a risk factor for priapism.
Priapismwhich occurs in approximately 42% of males with the SCD
has a mean age of onset of 13 years.2 However, the association of
priapism in hypogonadal males with SCD receiving testosterone
replacement therapy (TRT) has only been reported in the literature
twice. Furthermore the safety of TRT in adults with SCD has been
reported.3orrison).
Inc. This is an open access article uNon-treatment of hypogonadism in SCD presents challenges to
the adolescent. We report a case of an adolescent male with SCD
who had hypogonadism as well as frequent stuttering priapism
episodes and was treated successfully with TRT.Case presentation
A 14 year old Afro-Jamaican male with homozygous SCD was
referred to the Urology clinic at the Sickle Cell Unit, University of the
West Indies, Jamaica in July 2013. He reported a history of stuttering
priapism since age 8 years, occurring initially with a frequency of 3
nocturnal episodes weekly which progressed to 7 episodes weekly.
He reported two prior major episodes of priapism which required
penile aspiration. His mother reported concerns that since age
9 years he appeared small for his age.
On examination he was noted to have a small stature (weight
and height were below the third centile) and features in keeping
with delayed puberty. His stretched penile length was 11.5 cm.
His testes werew10 mls in volume bilaterally.
He was referred to the pediatric endrocrine clinic. Serum early
morning total testosterone, luteinizing hormone (LH), follicle
stimulating hormone (FSH) and cortisol were requested. Early
morning total testosteronewas 1.7 nmol/L (50 ng/dl), LHwas 2.4 IU/
L and FSH was 2.6 IU/L. Early morning and afternoon cortisol were
182 nmol/L (normal range: 138e689.8 nmol/l) and 75 nmol/Lnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Total testosterone levels (ng/dl) and priapism frequency
Total testosterone
levels (ng/dl)
Monthly priapism
frequency (n)
Baseline 50 28
At 11 months of testosterone
replacement therapy
210 0
B.F. Morrison et al. / Urology Case Reports 3 (2015) 179e180180(55.2e331.1 nmol/l). Radiological assessment of bone age
corresponded to an age of 10 years.
He was diagnosed with a delayed puberty and was commenced
on testosterone enanthate 50 mg intramuscularly every 4 weeks
and increased by 25 mg every 4 months. Serum testosterone
increased to 7.3 nmol/L (210 ng/dL) after 11months of TRT (Table 1).
Improvements in anthropometric measures were noted during TRT,
with increase in height and stretched penile length. Within
3 months of TRT, he noted a single major priapism episode occur-
ring approximately 1 week after TRT injection, requiring penile
aspiration. He however noted an overall reduction in the frequency
of stuttering episodes with no priapism episodes noted in the last
12 months of treatment. He has reported preservation of normal
sleep-related erections.
Discussion
TRT was able to successfully resolve delayed puberty. Though
there is no current guideline in management of adolescent males
with hypogonadism, there are successful reports of reversal of
delayed puberty after receiving short or long-term androgen ther-
apy.1 TRT shows beneﬁt in improving bone mass, body composition
and improving psychological distress in males with delayed
puberty.
Reduced testosterone levels are seen in 29% of males with SCD.3
The etiology is unknown with reports suggesting a mechanism of
primary hypogonadism due to possible testicular infarcts or sec-
ondary hypogonadism due to pituitary or hypothalamic dysfunc-
tion. A recent study with a mouse model of SCD designed to
determine the mechanism of testosterone deﬁciency revealed
reduced serum and intratesticular testosterone levels in SCD versus
wild type mice. In addition LH levels were elevated conﬁrming a
primary cause of hypogonadism. The proposed mechanism was
impairment in the Leydig cell steroidogenic pathway secondary to
increased oxidative stress and NADPH oxidase activation in the SCD
testis.4 There is variation in the severity of endocrine abnormalities
in SCD which directly correlates with the severity of the hemo-
globinopathy. Other determinants of delayed puberty in SCD
include nutritional factors and high resting energy expenditure.Androgens play an important role in early penile development.
Suppression of neonatal androgen levels results in reduced
expression of corpora cavernosal phosphodiesterase type 5 (PDE5)
enzymes, which terminate nitric oxide (NO)-induced cGMP-
mediated cavernosal smooth muscle relaxation, as well as loss of
cavernosal smooth muscle cells ultimately leading to disorders of
penile function. Nitric oxide synthase (NOS) synthesizes NO, a vital
molecule in the physiology of erections. The expression of NOS is
regulated by androgens, with androgen withdrawal reducing levels
of NOS and testosterone replacement increasing its levels. The
pathophysiology of priapism in SCD has been linked to abnormal
NOS activity/reduced NO bioavailability in the penis. Transgenic
sickle-cell mice have reductions in penile NO/cGMP signaling
leading to deﬁcient PDE5 function and uncontrolled erectile
responses.5 The dysregulation of the NO/NOS system in SCD results
in disorders of penile tumescence and detumescence resulting in
priapism. It is believed that this abnormal molecular signaling in
SCD is worsened by hypogonadism.3 We therefore suggest that TRT
may improve rather than worsen priapism episodes in SCD since it
reverses the molecular abnormalities involving the NO/c GMP/
PDE5 system.3
In summary, we report on a case of hypogonadism in adoles-
cents with SCDwhere TRT improved delayed puberty.We are aware
of the limitation of the modest follow-up period. Appropriate
duration of therapy for these adolescents is undetermined. We
believe our ﬁndings support consideration of TRT in these patients
and also warrant further controlled studies on the beneﬁt of
androgens in males with SCD.
Conclusion
The report represents a case of hypogonadism in SCD where TRT
improved delayed puberty without worsening priapism.
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